Related Experiment Videos
Prostate cancer gene therapy: past experiences and future promise
Thomas A Gardner1, James Sloan, Sudhanshu P Raikwar
1Department of Urology, Microbiology and Immunology and Walther Oncology Center, Indiana University Medical Center, Indianapolis, IN 46202, USA. thagardn@iupui.edu
Abstract:
Gene therapy has been used to target prostate cancer with excellent pre-clinical efficacy but limited clinical efficacy. The concept of delivering genetic material to prostate cancer cells to alter their phenotype and ultimately their behavior has been demonstrated in the laboratory over the last decade. Translating those pre-clinical findings into novel therapies for prostate cancer has been difficult. The stigma of gene therapy and the aggressive regulation of clinical trials involving transfer of genetic material to patients are two major impediments to clinical successes in gene therapy. This review hopes to provide a snapshot of prior gene transfer protocol findings and forecast the exciting future directions investigators are heading.
Insights
Gene therapy shows promise for prostate cancer in labs but faces clinical hurdles. This review covers past gene transfer findings and future research directions for this cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Gene therapy has demonstrated significant pre-clinical efficacy in targeting prostate cancer.
- The fundamental concept involves delivering genetic material to modify prostate cancer cell behavior.
- Translating laboratory successes into effective clinical treatments for prostate cancer remains a challenge.
Purpose of the Study:
- To review prior gene transfer protocol findings in prostate cancer research.
- To identify impediments to clinical success in prostate cancer gene therapy.
- To forecast future research directions in the field.
Main Methods:
- Review of existing literature on gene transfer protocols for prostate cancer.
- Analysis of pre-clinical and clinical study outcomes.
- Identification of regulatory and societal factors impacting gene therapy trials.
Main Results:
- Pre-clinical studies show high efficacy, but clinical translation is limited.
- Stigma associated with gene therapy and stringent regulations hinder clinical progress.
- Despite challenges, promising future directions are emerging for gene therapy in prostate cancer.
Conclusions:
- Gene therapy holds potential for prostate cancer treatment, but clinical application requires overcoming significant barriers.
- Further research and streamlined regulatory pathways are crucial for advancing gene therapy for prostate cancer.
- The field is progressing towards innovative strategies to enhance clinical efficacy and patient outcomes.